CZ20011021A3 - Způsoby tlumení imunitní odpovědi na terapeutické proteiny - Google Patents

Způsoby tlumení imunitní odpovědi na terapeutické proteiny Download PDF

Info

Publication number
CZ20011021A3
CZ20011021A3 CZ20011021A CZ20011021A CZ20011021A3 CZ 20011021 A3 CZ20011021 A3 CZ 20011021A3 CZ 20011021 A CZ20011021 A CZ 20011021A CZ 20011021 A CZ20011021 A CZ 20011021A CZ 20011021 A3 CZ20011021 A3 CZ 20011021A3
Authority
CZ
Czechia
Prior art keywords
agent
antibody
factor viii
cell
antibodies
Prior art date
Application number
CZ20011021A
Other languages
Czech (cs)
English (en)
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Original Assignee
Genetics Institute, Inc.
American Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc., American Red Cross filed Critical Genetics Institute, Inc.
Publication of CZ20011021A3 publication Critical patent/CZ20011021A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CZ20011021A 1998-09-21 1999-09-21 Způsoby tlumení imunitní odpovědi na terapeutické proteiny CZ20011021A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21

Publications (1)

Publication Number Publication Date
CZ20011021A3 true CZ20011021A3 (cs) 2001-10-17

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011021A CZ20011021A3 (cs) 1998-09-21 1999-09-21 Způsoby tlumení imunitní odpovědi na terapeutické proteiny

Country Status (21)

Country Link
EP (1) EP1115423A1 (zh)
JP (1) JP2002526455A (zh)
KR (1) KR20010085830A (zh)
CN (1) CN1331602A (zh)
AU (1) AU761206B2 (zh)
BR (1) BR9913991A (zh)
CA (1) CA2343916A1 (zh)
CZ (1) CZ20011021A3 (zh)
EA (1) EA005236B1 (zh)
HK (1) HK1039059A1 (zh)
HU (1) HUP0103960A3 (zh)
IL (1) IL142069A0 (zh)
LT (1) LT4920B (zh)
LV (1) LV12768B (zh)
MX (1) MXPA01002898A (zh)
NO (1) NO20011412L (zh)
NZ (1) NZ511034A (zh)
PL (1) PL346796A1 (zh)
SI (1) SI20626A (zh)
WO (1) WO2000016801A1 (zh)
ZA (1) ZA200103156B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE60118362T2 (de) * 2000-05-19 2007-05-24 The Center for Blood Research, Inc., Boston VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN
US7040139B2 (en) * 2003-06-10 2006-05-09 Smiths Detection Inc. Sensor arrangement
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
CN1261285A (zh) * 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗
US8082673B2 (en) 2009-11-06 2011-12-27 Hexagon Metrology Ab Systems and methods for control and calibration of a CMM

Also Published As

Publication number Publication date
EA200100385A1 (ru) 2001-10-22
LV12768A (en) 2001-12-20
NO20011412L (no) 2001-05-16
HK1039059A1 (zh) 2002-04-12
LV12768B (lv) 2002-06-20
CN1331602A (zh) 2002-01-16
ZA200103156B (en) 2002-07-18
EP1115423A1 (en) 2001-07-18
HUP0103960A2 (hu) 2002-02-28
AU761206B2 (en) 2003-05-29
LT2001045A (en) 2002-01-25
NO20011412D0 (no) 2001-03-20
AU6057899A (en) 2000-04-10
IL142069A0 (en) 2002-03-10
EA005236B1 (ru) 2004-12-30
KR20010085830A (ko) 2001-09-07
LT4920B (lt) 2002-06-25
PL346796A1 (en) 2002-02-25
SI20626A (sl) 2002-02-28
WO2000016801A1 (en) 2000-03-30
BR9913991A (pt) 2001-07-03
HUP0103960A3 (en) 2003-09-29
JP2002526455A (ja) 2002-08-20
NZ511034A (en) 2004-03-26
WO2000016801A9 (en) 2000-10-26
MXPA01002898A (es) 2002-06-04
CA2343916A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
JP5580535B2 (ja) 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
US20120269806A1 (en) Methods of inducing tolerance
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
JP2020105219A (ja) 癌治療のための改善された細胞組成物および方法
AU657255B2 (en) Monoclonal antibodies for inducing tolerance
US20210340214A1 (en) Cd80 extracellular domain fc fusion protein dosing regimens
US20210002373A1 (en) KLRG1 Binding Compositions and Methods of Use Thereof
US20070092506A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
CZ20011021A3 (cs) Způsoby tlumení imunitní odpovědi na terapeutické proteiny
US20030161827A1 (en) Therapies that improve graft survival
EP4110802A1 (en) Cd80 extracellular domain fc fusion protein therapy
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
Bril Factor VIII inhibitors in mild haemophilia A
Miao et al. Immunomodulation of transgene responses following naked DNA transfer
AU3437902A (en) Methods for modulating T cell unresponsiveness